PZP

Across TCGA pan-cancer cohorts, PZP mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PZP data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PZP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PZP expression acts as an unfavorable survival marker, although some lineages such as OV and GBM show a favorable association.

LUAD, OV, and GBM are the cancer types where PZP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.281	0.837	.006	12	view →
OV	DFS	Median	All	1.000	0.684	.024	4	view →
GBM	DFS	Quartile	All	0.498	0.190	.016	4	view →
CCRCC	DFS	Quartile	III,IV	0.233	0.830	.038	3	view →
LSCC	DFS	Median	All	0.908	0.971	.030	3	view →
PDAC	OS	Quartile	III,IV	0.302	0.850	.020	3	view →
HNSC	OS	Median	III,IV	0.948	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PZP–LUAD (DFS)

Open the LUAD breakdown →